Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy...( Optivus Proton Therapy Inc. Teams wit...),Health

Optivus Proton Therapy, Inc. Teams with Parsons Commercial Technology Group

Inc. to Produce Proton Beam Treatment Centers Globally

LOS ANGELES, Oct. 29 /PRNewswire/ -- Yesterday, at the 49th Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), Optivus Proton Therapy, Inc. (Optivus(R)) and Parsons Commercial Technology Group Inc., a global business unit of Parsons Corporation, announced a historic teaming agreement has been formalized between the two companies to globally produce turn-key proton beam therapy centers.

"The agreement between the teams of Optivus and Parsons will assure our clients that their proton system will be completed on time by the most expert team in the field," said Jon Slater, Optivus President and CEO. "This is a win/win/win situation for Optivus, Parsons and our clients."

Founded in 1944, Parsons is one of the largest 100% employee-owned management, engineering, and construction companies in the United States.

"Parsons collaborates with innovators and leaders in many diversified markets. We are thrilled to add the development of proton beam therapy centers, with Optivus, to our wide-ranging portfolio," said John Small, Parsons Group President.

Optivus was formed by the engineers who designed and installed the world's first and most successful hospital-based proton center at Loma Linda University Medical Center in Loma Linda, California. The facility commissioned and maintained by Optivus has enjoyed more success than all other comparable competitors' systems, with higher throughput, the most patients treated, and the most types of diseases treated with the most reliable and efficient device on the market.

"Interest in the development of proton treatment centers has grown at an enormous rate in recent years and can largely be attributed to our successes," Slater said. "This development will further reinforce our position as the global leader in proton therapy t
'/>"/>